Abstract:Piroxicam (PRX), a potent nonsteroidal anti-inflammatory drug, is prescribed to relieve postoperative and/or chronic joint pain. However, its oral administration often results in serious gastrointestinal adverse effects including duodenal ulceration. Thus, a novel cationic nanoparticle (NP) was explored to minimize the systemic exposure and increase the retention time of PRX in the joint after intra-articular (IA) injection, by forming micrometer-sized electrostatic clusters with endogenous hyaluronic acid (HA) in the synovial cavity. PRX-loaded NPs consisting of poly(lactic-co-glycolic acid), Eudragit RL, and polyvinyl alcohol were constructed with the following characteristics: particle size of 220 nm, zeta potential of 11.5 mV in phosphate-buffered saline, and loading amount of 4.0% (w/w) of PRX. In optical and hyperspectral observations, the cationic NPs formed more than 50 μm-sized aggregates with HA, which was larger than the intercellular gaps between synoviocytes. In an in vivo pharmacokinetic study in rats, area under the plasma concentration-time curve (AUC0-24 h) and maximum plasma concentration (Cmax) of PRX after IA injection of the cationic NPs were <70% (P<0.05) and 60% (P<0.05), respectively, compared to those obtained from drug solution. Moreover, the drug concentration in joint tissue 24 h after dosing with the cationic NPs was 3.2-fold (P<0.05) and 1.8-fold (P<0.05) higher than that from drug solution and neutrally charged NPs, respectively. Therefore, we recommend the IA cationic NP therapy as an effective alternative to traditional oral therapy with PRX, as it increases drug retention selectively in the joint.

[Comparison of Concentration of Piroxicam in Blood and Local Site after Two Routes of Administration].

[Comparison Between the Characteristics of Absorption and Pharmacokinetic Behavior of Ginsenoside Rg1 and Ginsenoside Rb, of Panax Notoginseng Saponins].

Bioavailability of piroxicam transdermal preparations in human volunteers

The Percutaneous Absorption Potential of Two Kinds of Piroxicam Gels:A Comparative Study in Vitro

Preparation and relative bioavailability in rabbits of piroxicam transdermal patch

Study on bioequivalence of cilostazol table in healthy volunteers

Study on preparation and percutaneous absorption in vitro of piroxicam microemulsion

Study on transdermal iontophoresis of piroxicam gel

Randomized clinical comparisons of diclofenac concentration in the soft tissues and blood plasma between topical and oral applications

Study on Percutaneous Permeation of Piroxicam and In-Vitro Evalution of Piroxicam Gels for Transdermal Delivery

Pharmacokinetics of piroxicam-β-cyclodextrin inclusion complexes in Beagle dogs

An Investigation into the Effect of Various Penetration Enhancers on Percutaneous Absorption of Piroxicam

Development of salting-out extraction methodology for the determination of piroxicam from polymeric based nanocarriers and biological samples

[Comparison of bioavailability of two kinds of solid dispersion from 10-hydroxycamptothecin in SD rats in vivo].

[Comparative study on absorption kinetics in intestines of rats of epimedii foliunm of Xianlinggubao capsules prepared by different processes]

Increased localized delivery of piroxicam by cationic nanoparticles after intra-articular injection

Two different strategies for the fluorimetric determination of piroxicam in serum

Pharmacodynamics of piroxicam from self-emulsifying lipospheres formulated with homolipids extracted from Capra hircus

Comparison of Pharmacokinetics of Baicalein and Baicalin in Rats

Bioequivalence of domestic and imported bisoproloi tablets

Comparative pharmacokinetics of prim-O-glucosylcimifugin and cimifugin by liquid chromatography-mass spectrometry after oral administration of Radix Saposhnikoviae extract, cimifugin monomer solution and prim-O-glucosylcimifugin monomer solution to rats.